• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Anika Appoints Sheryl Conley to Board of Directors

    11/1/21 9:00:00 AM ET
    $ANIK
    $SRGA
    $STIM
    Medical/Dental Instruments
    Health Care
    Industrial Specialties
    Health Care
    Get the next $ANIK alert in real time by email

    BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021.

    Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management, marketing, sales, product development and operations. Ms. Conley will serve on the Audit Committee. This appointment brings the total number of independent directors to seven.

    "We are pleased to have Sheryl join our Board of Directors as Anika executes on its strategy to transform into a leading joint preservation company," commented Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika. "I have known Sheryl for many years as an innovator and leader in the orthopedic industry and her commercial experience in orthopedics is second to none. She spent more than 25 years at Zimmer in escalating management roles, including as Group President across a variety of product segments and geographies, during which she provided key leadership in the development and commercialization of over 50 industry leading brands. We are very excited for her to bring those experiences to the Anika Board."

    Jeff Thompson, Anika's Chair of the Board, commented, "Adding Sheryl brings a high degree of industry knowledge, including significant experience in operating fully integrated orthopedic businesses, which will help guide Anika through its transformational journey as it becomes a leading joint preservation company. I look forward to working with Sheryl in her new role."

    Sheryl Conley is currently President and Board Member of AcceLINX, Inc., a musculoskeletal health business accelerator. She also serves on the Board of Directors for Neuronetics, Inc. (NASDAQ:STIM), since October 2019, where she is a member of the Audit and Nominating and Governance Committees. She also serves on the Board for Surgalign, Inc. (NASDAQ:SRGA), since May 2021, where in addition to her role as Chair, she is a member of the Audit Committee. She holds a Bachelor of Science (Biology and Chemistry) and an MBA from Ball State University (IN).

    About Anika

    Anika Therapeutics, Inc. (NASDAQ:ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit www.anika.com.

    For Investor Inquiries:

    Anika Therapeutics, Inc.

    Mark Namaroff, 781-457-9287

    Executive Director, Investor Relations and Corporate Communications

    [email protected]



    Primary Logo

    Get the next $ANIK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANIK
    $SRGA
    $STIM

    CompanyDatePrice TargetRatingAnalyst
    Anika Therapeutics Inc.
    $ANIK
    4/17/2025$21.00Buy
    B. Riley Securities
    Anika Therapeutics Inc.
    $ANIK
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    Neuronetics Inc.
    $STIM
    8/13/2024Outperform → Mkt Perform
    William Blair
    Anika Therapeutics Inc.
    $ANIK
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    Anika Therapeutics Inc.
    $ANIK
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    Anika Therapeutics Inc.
    $ANIK
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    Anika Therapeutics Inc.
    $ANIK
    10/14/2022$26.00Equal-Weight
    Stephens
    Anika Therapeutics Inc.
    $ANIK
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    More analyst ratings

    $ANIK
    $SRGA
    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Madryn Asset Management, Lp sold $13,020,000 worth of shares (3,500,000 units at $3.72) (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    8/12/25 4:15:10 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Pfanstiel Steven

    3 - Neuronetics, Inc. (0001227636) (Issuer)

    7/15/25 5:00:06 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    EVP, CFO and Treasurer Pfanstiel Steven was granted 400,000 shares (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    7/15/25 5:00:04 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $ANIK
    $SRGA
    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards

    8/6/25 4:45:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Reports Second Quarter 2025 Financial and Operating Results

    Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to $3.5 million, beating guidance of under $5 million In August 2025, received an additional $10 million in funding under the existing debt agreement with Perceptive Advisors LLC MALVERN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need he

    8/5/25 7:05:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

    MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 1:30pm Eastern Time the same day.The presentation will be available via the conference portal to registered attendees and presenting companies for 14 days following th

    8/4/25 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $ANIK
    $SRGA
    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/13/24 5:02:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/6/24 5:05:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    8/30/24 5:15:02 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $ANIK
    $SRGA
    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ANIK
    $SRGA
    $STIM
    SEC Filings

    View All

    B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

    B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Anika Therapeutics with a new price target

    Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

    11/1/24 10:25:08 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    8/13/24 10:26:16 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Neuronetics Inc.

    144 - Neuronetics, Inc. (0001227636) (Subject)

    8/8/25 4:54:08 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Neuronetics Inc.

    424B5 - Neuronetics, Inc. (0001227636) (Filer)

    8/6/25 4:30:21 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Neuronetics Inc.

    10-Q - Neuronetics, Inc. (0001227636) (Filer)

    8/5/25 7:31:19 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $ANIK
    $SRGA
    $STIM
    Financials

    Live finance-specific insights

    View All

    Anika Reports Second Quarter 2025 Financial Results

    Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025 Reaffirming Fiscal 2025 Revenue and EBITDA guidance; revising long-term outlook to reflect potential timing of FDA review for Hyalofast launch BEDFORD, Mass., July

    7/30/25 7:05:25 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2025 financial and operating results prior to market open on Tuesday, August 5, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/d6qidqaw. To listen to the conference call on your telephone, participants may register for t

    7/22/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025

    BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 48251. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.ani

    7/16/25 4:01:18 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    $SRGA
    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 1:42:23 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 11:17:47 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $ANIK
    $SRGA
    $STIM
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints New Chief Financial Officer

    Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Steven Pfanstiel has been appointed as the company's new Chief Financial

    7/15/25 7:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

    MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strate

    6/2/25 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care